Latest News

Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.

How this gene-agnostic optogenetic approach could fill a critical gap for advanced inherited retinal degeneration.

Length and width, not thickness, emerge as key drivers of higher-order aberrations.

Border zone lifetime gradient correlated with growth rate over 5 years

Real-world data support EndoArt as donor-independent option in high-risk patients

Varicella vaccine drove the largest risk reduction in a 5-vaccine, multi-million-patient analysis

Biologic therapies linked to high remission rates over 2-year follow-up

In this Q&A, Dipanjan Pan, PhD, breaks down the science behind the COSMIC tear biosensor platform and what it will take to bring it to clinical use.

What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape